Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.

Varanasi: An 18-year-old boy with a complex congenital cardiac abnormality was operated on successfully in the ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its ...

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, presented results from an expanded cohort of 500 patients in the ALIGN-AR Pivotal Trial ...